Parmeet Ahuja was named Chief Financial Officer of Maxcyte, Inc., effective March 30, 2026. As of November 14, 2026, Maxcyte, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 27, 2026, naming 1 appointment (Form 8-K, March 27, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Maxcyte, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Maxcyte, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-27. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Maxcyte, Inc. files it.
Layoffs on record: 1 filing or notice, latest 2024-12-09 (layoff filings and notices).
Also on the record for Maxcyte, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 2, 2026 | Stake report, Schedule 13D, by Liontrust Investment Partners LLP | 4.9% of the class | 5%+ stakes | Source |
| October 15, 2026 | Stake report, Schedule 13D, by Liontrust Investment Partners LLP | 5% of the class | 5%+ stakes | Source |
| August 4, 2026 | Stake report, Schedule 13D, by RIVER GLOBAL INVESTORS LLP | 0.8% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 1.3% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13D, by RIVER GLOBAL INVESTORS LLP | 6.1% of the class | 5%+ stakes | Source |
| April 10, 2026 | Stake report, Schedule 13G/A, by Mirabella Financial Services LLP | — | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Cadian Capital Management, LP | 3.5% of the class | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G, by Capricorn Fund Managers Ltd | 7.7% of the class | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 6.6% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Cadian Capital Management, LP | 7.7% of the class | 5%+ stakes | Source |
| November 4, 2025 | Stake report, Schedule 13G/A, by Mirabella Financial Services LLP | 7.69% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Maxcyte, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Maxcyte, Inc. and the records around it.
Maxcyte, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Capricorn Fund Managers Ltd also filed stake reports on 3 other companies: Blend Labs, Inc. (Oct 2026), KINGSWAY Corp (Jul 2026), Beauty Health Co (Jul 2026)
- Mirabella Financial Services LLP also filed stake reports on 3 other companies: Kingsway Financial Services Inc (Apr 2026), Beauty Health Company (Feb 2026)
- Cadian Capital Management, LP also filed stake reports on 7 other companies: Cryoport, Inc. (Aug 2026), Flywire Corp. (Aug 2026), SI-BONE, Inc. (Aug 2026)
Watch Maxcyte, Inc.
Get an email when Maxcyte, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Maxcyte, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Maxcyte, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Maxcyte, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-27 | In | Chief Financial Officer | 2026-03-30 | 8-K, 2026-03-27 |
Who leads Maxcyte, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Parmeet Ahuja, appointed, effective 2026-03-30 (filed 2026-03-27).
New leaders reset buying decisions — get the Full Report on Maxcyte, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Maxcyte, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Maxcyte, Inc.Every change, in the filing's words
Appointed: Parmeet Ahuja, Chief Financial Officer, effective 2026-03-30
On March 23, 2026, the Board of Directors (the " Board ") of MaxCyte, Inc. (the " Company ") appointed Parmeet Ahuja as the Company's Chief Financial Officer, effective March 30, 2026.
- Mr. Ahuja will also serve as the Company's principal accounting officer.
- Mr. Ahuja succeeds Douglas Swirsky, who is transitioning from the role as previously announced in November 2025.
- Prior to joining MaxCyte, Mr. Ahuja, 57, served as Vice President, Investor Relations of Agilent Technologies, Inc., a life sciences tools company, ("Agilent") from August 2021 to October 2025, and previously served as Vice President, Financial Planning and Analysis, Operations and Supply Chain at Agilent from July 2017 to July 2021.
- Mr. Ahuja brings over 20 years of finance leadership experience across a global, publicly traded, life sciences organization.
- Previously, he held several leadership roles at Agilent in operational finance, financial planning and analysis, enterprise audit and controls, and global financial operations.
- Mr. Ahuja holds an MBA from San Jose State University and a Bachelor of Commerce (Hons) from Delhi University.
- Mr. Ahuja will receive an annual base salary of $450,000 and will be eligible to receive an annual cash performance bonus with an initial target bonus percentage equal to 50% of his base salary.
Tools for this story
Each opens in a new tab, filled in for Maxcyte, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
